Association of proteolysis factors with progression of autosomal dominant polycystic kidney disease in children
- Authors: Bashirova Z.R.1, Osmanov I.M.2
-
Affiliations:
- Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University
- Children's City Clinical Hospital named after Z.A. Bashlyaeva of the Moscow Healthcare Department
- Issue: Vol 13, No 4 (2021)
- Pages: 53-60
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/273810
- DOI: https://doi.org/10.18565/nephroiogy.2021.4.53-60
- ID: 273810
Cite item
Abstract
Background. Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease with an incidence of 1:400 to 1:1000, accounting for 7-10% of all patients with end-stage chronic renal disease. Predicting the rate of disease progression has become especially important today with the advent of tolvaptan, the first drug modifying ADPKD. Patients with a high likelihood of rapid disease progression should be selected for this treatment, as these patients are expected to have an optimal benefit/risk ratio. The system of matrix metalloproteinases (MMPs) and their inhibitors (tissue inhibitors of MMP - TIMP, type 1 plasminogen activator inhibitor - PAI-I) plays a key role in the processes of proteolysis in the kidney. Objective. Determination of the blood serum levels of MMP-2, -3 and -9 and their inhibitors TIMP-1 and -2, PAI-I and their urinary excretion, estimating of the relationship of their changes with the ADPKD progression type, and assessment of the significance of disturbances in the MMP/TIMP system as an additional criterion for the progression of ADPKD. Material and methods. The study included 36 children with ADPKD who were admitted to the Department of Hereditary and Acquired Kidney Diseases named after Prof. M.S. Ignatova of the Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University. The levels of MMP-2, MMP-3 and MMP-9 and their inhibitors TIMP-1 and -2, and PAI-I in blood serum and urine were determined by enzyme-linked immunosorbent assay. Results. As a result of the analysis of the frequency of changes in proteolysis factors in blood and urine in children with ADPKD, depending on the disease progression type (slow progression/progression), the following data were obtained: in children with ADPKD progression, the frequency of increase in the level of TIMP-I in the blood (P=0.010; Cramer's V=0.479; OR=12; 95% CI, 1.79-80.3)) and urine (P=0.015; Cramer's V=0.482; OR=9.8; 95% CI, 1.84-51.9)) was statistically significantly higher. Also, the level of PAI-I in the blood (P=0.039; Cramer's V=0.396) and urine (P=0.022; Cramer's V=0.444) was statistically significantly higher in children with ADPKD progression. The chances of a progressive course increased by 6.3 times (95% CI, 1.27-31.2) with an increase in blood PAI-I level and by 9.0 times (95% CI, 1.55-52.2) with an increase in urine PAI-I level in children with progressive ADPKD compared to slow progression. Conclusion. The ADPKD progression in childhood is manifested by an increase in the number of cysts and in the size of the kidneys with the preserved filtration function of the kidneys for a long time due to hyperfiltration. This study identifies children at risk for rapid kidney enlargement, i.e. a progressive course that may benefit from therapeutic interventions in the future. The data obtained from this study indicate that TIMP-1 and PAI-I can be considered as risk factors for the progression of ADPKD in children
Full Text
About the authors
Zilya R. Bashirova
Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University
Email: z-bash@mail.ru
Researcher of the Department of Hereditary and Acquired Kidney Diseases named after Prof. M.S. Ignatova
Ismail M. Osmanov
Children's City Clinical Hospital named after Z.A. Bashlyaeva of the Moscow Healthcare DepartmentDr. Sci. (Med.), Professor, Chief Physician of the Children's City Clinical Hospital named after Z.A. Bashlyaeva of the Moscow Healthcare Department, Chief Pediatrician, Chief Pediatric Nephrologist of the Moscow Healthcare Department
References
- Ong A.C.M., Devuyst O., Knebelmann B., et al. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015;385:1993-2002. https://doi.org/10.1016/S0140-6736(15)60907-2
- Wong A.T.Y., Mannix C., Grantham J.J., et al. Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ. Open 2018;8:e018794. https://doi.org/10.1136/bmjopen-2017-018794
- He W.-B., Xiao W.-J., Tan Y.-Q., et al. Novel mutations of PKD genes in Chinese patients suffering from autosomal dominant polycystic kidney disease and seeking assisted reproduction. BMC. Med. Genet. 2018;19:186. https://doi.org/10.1186/s12881-018-0693-7
- De Rechter S., Breysem L., Mekahli D. Is Autosomal Dominant Polycystic Kidney Disease Becoming a Pediatric Disorder? Front. Pediatr. 2017;5:272. https://doi.org/10.3389/fped.2017.00272.
- Cornec-Le Gall E., Audrezet M.-P., Chen J.-M., et al. Type of PKD1 mutation influences renal outcome in ADPKD. J. Am. Soc. Nephrol. 2013;24:1006-13. https://doi.org/10.1681/ASN.2012070650
- Torres V.E., Chapman A.B., Devuyst O., et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 2012;367:2407-18. https://doi.org/10.1056/NEJMoa1205511
- Torres V.E., Chapman A.B., Devuyst O., et al. Tolvaptan in Later -Stage Autosomal Dominant Polycystic Kidney Disease. N. Engl. J. Med. 2017;377:1930-42. https://doi.org/10.1056/NEJMoa1710030
- Chapman A.B., Devuyst O., Eckardt K.-U., et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015;88:17-27. https://doi.org/10.1038/ki.2015.59
- Gansevoort R.T., Arici M., Benzing T., et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol. Dial. Transplant. 2016;31: 337-48. https://doi.org/10.1093/ndt/gfv456
- Grantham J.J., Torres V.E., Chapman A.B., et al. Volume progression in polycystic kidney disease. N. Engl. J. Med. 2006;354:2122-30. https://doi.org/10.1056/NEJMoa054341
- Bhutani H., Smith V., Rahbari-Oskoui F., et al. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int. 2015;88:146-51. https://doi.org/10.1038/ki.2015.71
- Irazabal M.V., Rangel L.J., Bergstralh E.J., et al. Imaging Classification of Autosomal Dominant Polycystic Kidney Disease: A Simple Model for Selecting Patients for Clinical Trials. JASN. 2015;26:160-72. https://doi.org/10.1681/ASN.2013101138
- Cornec-Le Gall E., Audrezet M.-P., Chen J.-M., et al. Type of PKD1 Mutation Influences Renal Outcome in ADPKD. J. Am. Soc. Nephrol. 2013;24:1006-13. https://doi.org/10.1681/ASN.2012070650
- Cornec-Le Gall E., Audrezet M.-P., Rousseau A., et al. The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease. J. Am. Soc. Nephrol. 2016;27:942-51. https://doi.org/10.1681/ASN.2015010016
- Rockey D.C., Bell P.D., Hill J.A. Fibrosis-A Common Pathway to Organ Injury and Failure. N. Engl. J. Med. 2015;373:96. https://doi.org/10.1056/NEJMc1504848
- Eddy A.A. Can renal fibrosis be reversed? Pediatr. Nephrol. 2005;20:1369-75. https://doi.org/10.1007/s00467-005-1995-5
- Eddy A.A. Molecular basis of renal fibrosis. Pediatr. Nephrol. 2020;15:290-301. https://doi.org/10.1007/s004670000461
- A Meguid El Nahas., Bello A.K. Chronic kidney disease: the global challenge. Lancet. 2005;365:331-40. https://doi.org/10.1016/S0140-6736(05)17789-7
- Bicer A., Guclu B., Ozkan A., et al. Expressions of angiogenesis associated matrix metalloproteinases and extracellular matrix proteins in cerebral vascular malformations. J. Clin. Neurosci. 2010;17:232-36. https://doi.org/10.1016/j.jocn.2009.06.008.
- Duffield J.S. Cellular and molecular mechanisms in kidney fibrosis. J. Clin. Invest. 2014;124:2299-306. https://doi.org/10.1172/JCI72267
- Norman J. Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD). Biochim. Biophys. Acta. 2011;1812:1327-36. https://doi.org/10.1016/j.bbadis.2011.06.012.
- Jeremy S. Duffield. Cellular and molecular mechanisms in kidney fibrosis. J. Clin. Invest. 2014;124(6):2299-306. doi: 10.1172/JCI72267.
- Nagase H., Woessner J.F. Matrix metalloproteinases. J. Biol. Chem. 1999;274:21491-94. https://doi.org/10.1074/jbc.274.31.21491
- Бобкова И.Н., Козловская Л.В., Ли О.А. Рольматриксныхметаллопротеиназ в патогенезе заболеваний почек. Тер. архив. 2008;6:86-90. [Bobkova I.N., Kozlovskaia L.V., Li O.A. The role of matrix metalloproteinases in pathogenesis of renal disease. Ter Arkh. 2008;80(6):86-90 (In Russ.)].
- Catania J.M., Chen G., Parrish A.R. Role of matrix metalloproteinases in renal pathophysiologies. Am. J. Physiol. Renal. Physiol. 2007;292:F905-11. https://doi.org/10.1152/ajprenal.00421.2006
- Keeling J., Herrera G.A. Human matrix metalloproteinases: characteristics and pathologic role in altering mesangial homeostasis. Microsc. Res. Tech. 2008;71:371-9. https://goi.org/16.1662/jemt.26585
- Sternlicht M.D. How matrix metalloproteinases regulate cell behavior. Ann. Rev. Cell. Dev. Biol. 2001;17:463-516. doi: 10.1146/annurev.cellbio.17.1.463.
- Woon C., Bielinski-Bradbury A., O'Reilly K., Robinson P. A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease. BMC. Nephrol. 2015;16:140. Doi: 10.1186/ s12882-015-0114-5.
- Chapman A.B., Bost J.E., Torres V.E., et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 2012;7(3):479-86. doi: 10.2215/CJN.09500911.
- Chapman A.B., Guay-Woodford L.M., Grantham J.J., et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int. 2663;84:1635-45. doi: 16.1648/j.1523-1755.2663.66125.x.
- Lacquaniti A., Chirico V., Lupica R., et al. Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease. Peptides. 2013;49:1-8. doi: 10.1016/j.peptides.2013.08.007
- Thong K.M., Ong A.C.M. The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre. QJM. 2013;106:639- 46. doi: 10.1093/qjmed/hct082
- Higashihara E., Nutahara K., Okegawa T., et al. Kidney volume and function in autosomal dominant polycystic kidney disease. Clin. Exp. Nephrol. 2614;12:157-85. doi: 16.1667/s16157-613-6234-4.
- Gabow P.A., Kimberling W.J., Strain J.D., et al. Utility of ultrasonography in the diagnosis of autosomal dominant polycystic kidney disease in children. J. Am. Soc. Nephrol. 1997;8:105-10. https://doi.org/10.1681/ASN.V81105
- Reed B., McFann K., Kimberling W.J., et al. Presence of De Novo Mutations in Autosomal Dominant Polycystic Kidney Disease Patients Without Family History. Am. J. Kidney Dis. 2662;52:1642-56. https://doi.org/86.8653/j.ajkd.2008.05.015
- Pei Y., Obaji J., Dupuis A., et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J. Am. Soc. Nephrol. 2009;20:205-12. https://doi.org/10.1681/ASN.2008050507
- Reed B., McFann K. Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. Am. J. Kidney Dis. 2008;52(6):1042.
- Levin A., Stevens P.E., Bilous R.W., et al. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 2013;3:1-150. https://doi.org/10.1038/kisup.2012.73
- Bakker J., Olree M., Kaatee R., et al. Renal volume measurements: accuracy and repeatability of US compared with that of MR imaging. Radiol. 1999;211:623-28. https://doi.org/10.1148/radiology.211.3.r99jn19623
- Scholbach T., Weitzel D. Body-surface-area related renal volume: a common normal range from birth to adulthood. Scientifica (Cairo) 2012:949164. https://doi.org/10.6064/2012/949164
- KUhn E.W., Walz G. The Treatment of Autosomal Dominant Polycystic Kidney Disease. Dtsch. Arztebl. Int. 2015;112:884-90. https://doi.org/10.3238/arztebl.2015.0884.
- Grantham J.J., Torres V.E., Chapman A.B., et al. Volume progression in polycystic kidney disease. N. Engl. J. Med. 2006;354:2122-30. https://doi.org/10.1056/NEJMoa054341.
- Bhutani H, Smith V., Rahbari-Oskoui F., et al. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int. 2015;88:146-51. https://doi.org/10.1038/ki.2015.71
- Leung V.Y., Chu W.C., Yeung C., et al. Nomograms of total renal volume, urinary bladder volume and bladder wall thickness index in 3,376 children with a normal urinary tract. Pediatr. Radiol. 2007;37:181-78. https://doi.org/10.1007/s00247-006-0376-y
- Meran S., Steadman R. Fibroblasts and myofibroblasts in renal fibrosis. Int. J. Exp. Pathol. 2011;92:158-67. https://doi.org/10.1111/j.1365-2613.2011.00764.x
- Ли О.А. Клиническое значение определения матриксных металлопротеиназ и их ингибиторов в ткани почки и моче при хроническом гломерулонефрите. Дисс. канд. мед. наук. М., 2011.
- Eddy A.A. Serine proteases, inhibitors and receptors in renal fibrosis. Thromb. Haemost. 2009;101:656- 64.
- Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 2003;92:827-39. https://doi.org/10.1161/01.RES.0000070112.80711.3D
- Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 2006;69:562-73. https://doi.org/10.1016/j.cardiores.2005.12.002
- Eddy A.A. Molecular basis of renal fibrosis. Pediatr. Nephrol. 2000;15:290 301. https://doi.org/10.1007/s004670000461
- Tan T.K., Zheng G., Hsu T.T., et al. Macrophage matrix metalloproteinase-9 mediates epithelial-mesenchymal transition in vitro in murine renal tubular cells. Am. J. Pathol. 2010;176:1256-70. doi: 10.2353/ajpath.2010.090188.
- Aresu L., Benali S., Garbisa S., et al. Matrix metalloproteinases and their role in the renal epithelial mesenchymal transition. Histol. Histopathol. 2011;26(3):307-13. doi: 10.14670/HH-26.307.
- Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Апп. Rev. Cell Dev. Biol. 2001;17:463-516. doi: 10.1146/annurev. cellbio.17.1.463.
- Ahmed A. Matrix Metalloproteinases and Their Inhibitors in Kidney Scarring: Culprits or Innocents. J. Health Sci. 2009;55:473-83. https://doi.org/10.1248/jhs.55.473
- Eddy A.A., Fogo A.B. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J. Am. Soc. Nephrol. 2006;17:2999-3012. https://doi.org/10.1681/ASN.2006050503
- Gomez D.E., Alonso D.F., Yoshiji H., Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 1997;74:111-22.
- Cai G., Zhang X., Hong Q., et al. Tissue inhibitor of metalloproteinase-1 exacerbated renal interstitial fibrosis through enhancing inflammation. Nephrol. Dial. Transplant. 2008;23:1861-75. https://doi.org/10.1093/ndt/gfm666
- Horstrup J.H., Gehrmann M., Schneider B., et al. Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease. Nephrol. Dial. Transplant. 2002;17:1005-13. https://doi.org/10.1093/ndt/17.6.1005